MedTrace Logo

CIRculating Cell-free nUcLeic Acids in Cancer Therapy Monitoring -01

NCT05871593 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-05-23

No results posted yet for this study

Summary

In cooperation with the molecular tumor board of the University Hospital Tübingen (UKT), a prospective collection of blood samples during the course of therapy is planned. It is a pilot study in which the technical feasibility of the approach (Highly Sensitive Next-Generation Sequencing (NGS) methods) initially should to be evaluated and further developed.

Conditions

  • Next-Generation-Sequencing

Interventions

GENETIC

Molecular genetic diagnostic

With the help of modern, highly sensitive analysis methods (NGS), such as ultra-low high-throughput sequencing, even the smallest amounts of circulating cell-free nucleic acids in the blood can be detected. In the individual course of therapy, the changes in concentration of the tumor-specific variants can thus be continuously monitored and appropriate therapy decisions can be made. The presence of minimal residual diseases and the development of resistance mutations can also be examined using this technique.

Sponsors & Collaborators

  • German Consortium for Translational Cancer Research

    collaborator OTHER

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Christopher Schroeder, Dr. · University Hospital Tübingen

  • Stephan Ossowski, Prof. Dr. · University Hospital Tübingen

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2025-10-31
Completion
2026-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05871593 on ClinicalTrials.gov